MetLife Investment Management’s Arcturus Therapeutics ARCT Stock Holding History

MetLife Investment Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$52.7K	Sell	6,825 -2,532	-27%	-$18.5K	﹤0.01%	2676
2025 Q4	$57.4K	Sell	9,357 -6,938	-43%	-$74.9K	﹤0.01%	2719
2025 Q3	$300K	Hold	16,295	–	–	﹤0.01%	2088
2025 Q2	$212K	Hold	16,295	–	–	﹤0.01%	2157
2025 Q1	$173K	Sell	16,295 -381	-2%	-$6.05K	﹤0.01%	2276
2024 Q4	$283K	Buy	16,676 +2,955	+22%	+$55.6K	﹤0.01%	2114
2024 Q3	$318K	Hold	13,721	–	–	﹤0.01%	2031
2024 Q2	$334K	Buy	13,721 +1,394	+11%	+$42.3K	﹤0.01%	1943
2024 Q1	$416K	Hold	12,327	–	–	﹤0.01%	1781
2023 Q4	$389K	Hold	12,327	–	–	﹤0.01%	1835
2023 Q3	$315K	Hold	12,327	–	–	﹤0.01%	1914
2023 Q2	$354K	Hold	12,327	–	–	﹤0.01%	1921
2023 Q1	$295K	Hold	12,327	–	–	﹤0.01%	1969
2022 Q4	$209K	Hold	12,327	–	–	﹤0.01%	2222
2022 Q3	$183K	Hold	12,327	–	–	﹤0.01%	2355
2022 Q2	$194K	Hold	12,327	–	–	﹤0.01%	2342
2022 Q1	$332K	Buy	12,327 +4,915	+66%	+$125K	﹤0.01%	2036
2021 Q4	$274K	Hold	7,412	–	–	﹤0.01%	1856
2021 Q3	$354K	Sell	7,412 -1,527	-17%	-$68.4K	﹤0.01%	1730
2021 Q2	$302K	Hold	8,939	–	–	﹤0.01%	1883
2021 Q1	$369K	Hold	8,939	–	–	﹤0.01%	1695
2020 Q4	$388K	Buy	8,939 +1,855	+26%	+$126K	﹤0.01%	1603
2020 Q3	$304K	Buy	7,084 +1,040	+17%	+$51.6K	﹤0.01%	1624
2020 Q2	$282K	Buy	+6,044	New	+$208K	﹤0.01%	1688

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MetLife Investment Management's ARCT Position: Q1 2026 in Review

MetLife Investment Management reduced its Arcturus Therapeutics (ARCT) stake by 27% in Q1 2026, selling an estimated $18.5K and leaving 6,825 shares worth $52.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2676.

MetLife Investment Management first reported a position in ARCT in Q2 2020 and has held it in 24 quarters since. The position peaked at $416K in Q1 2024. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

MetLife Investment Management held 6,825 shares of Arcturus Therapeutics worth $52.7K as of Q1 2026.
MetLife Investment Management sold 2,532 Arcturus Therapeutics shares in Q1 2026, an estimated $18.5K.
Arcturus Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2676 holding.
MetLife Investment Management first reported a position in Arcturus Therapeutics in Q2 2020 and has held it in 24 quarters since.
MetLife Investment Management's Arcturus Therapeutics position peaked at $416K in Q1 2024.
124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.